Fosun Pharma extends guarantees totaling over 350m yuan to subsidiaries

Shanghai Fosun Pharmaceutical Group (Fosun Pharma) has announced new guarantees for 14 of its controlled subsidiaries, totaling 350.51 million yuan. These guarantees are part of the group's approved and renewed guarantee limits, aiming to support the operational needs of its subsidiaries. The largest new guarantees include 100 million yuan for Fosun Health, 70 million yuan for Xingnuo Medicine, and 33 million yuan for Tianjin Jianjia Taida, with individual guarantees ranging from 5.5 million yuan to 100 million yuan.

The total actual external guarantee amount, including these new guarantees, stands at approximately 2,307,250 million yuan as of December 12, 2025. This represents 48.82% of the group's audited net assets as of December 31, 22024. All guarantees involve the company or its controlled subsidiaries.

Fosun Pharma emphasizes that these guarantees are deemed necessary and reasonable, posing a manageable risk to the company. There are no overdue guarantees reported as of December 12, 2025. A key risk identified is that some of the guaranteed entities have a debt-to-asset ratio exceeding 70%.